[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516513":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":233,"collaborators":24,"id":235,"slug":24,"hasResults":236,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":24,"eligibilityCriteria":240,"healthyVolunteers":236,"sex":241,"minAge":242,"maxAge":24,"enrollmentInfo":243,"targetDuration":24,"studyType":246,"phases":247,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":273},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Module 1: AZD5863 Monotherapy Intravenous (IV)","EXPERIMENTAL","Module 1: AZD5863 Intravenous (IV) Monotherapy",[13],"Drug: AZD5863",{"label":15,"type":10,"description":16,"interventionNames":17},"Module 2: AZD5863 Monotherapy Subcutaneous (SC)","Module 2: AZD5863 Subcutaneous (SC) Monotherapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","AZD5863","T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[32,45,54,63,72,77,84,93,101,110,118,126,135,143,151,160,165,170,175,184,192,200,209,217,225],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":24},"Research Site","RECRUITING","Jacksonville","Florida","32224","United States",{"type":40,"coordinates":41},"Point",[42,43],-81.65565,30.33218,{"lat":43,"lon":42},{"facility":33,"status":34,"city":46,"state":47,"zip":48,"country":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":24},"Rochester","Minnesota","55905",{"type":40,"coordinates":50},[51,52],-92.4699,44.02163,{"lat":52,"lon":51},{"facility":33,"status":55,"city":56,"state":56,"zip":57,"country":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":24},"WITHDRAWN","New York","10065",{"type":40,"coordinates":59},[60,61],-74.00597,40.71427,{"lat":61,"lon":60},{"facility":33,"status":34,"city":64,"state":24,"zip":65,"country":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":24},"Beijing","100142","China",{"type":40,"coordinates":68},[69,70],116.39723,39.9075,{"lat":70,"lon":69},{"facility":33,"status":34,"city":64,"state":24,"zip":73,"country":66,"cosmosGeoPoint":74,"geoPoint":76,"contacts":24},"101199",{"type":40,"coordinates":75},[69,70],{"lat":70,"lon":69},{"facility":33,"status":34,"city":78,"state":24,"zip":24,"country":66,"cosmosGeoPoint":79,"geoPoint":83,"contacts":24},"Shandong",{"type":40,"coordinates":80},[81,82],120.48412,40.28464,{"lat":82,"lon":81},{"facility":33,"status":34,"city":85,"state":24,"zip":86,"country":87,"cosmosGeoPoint":88,"geoPoint":92,"contacts":24},"Toulouse","31059","France",{"type":40,"coordinates":89},[90,91],1.44367,43.60426,{"lat":91,"lon":90},{"facility":33,"status":34,"city":94,"state":24,"zip":95,"country":87,"cosmosGeoPoint":96,"geoPoint":100,"contacts":24},"Villejuif","94805",{"type":40,"coordinates":97},[98,99],2.35992,48.7939,{"lat":99,"lon":98},{"facility":33,"status":34,"city":102,"state":24,"zip":103,"country":104,"cosmosGeoPoint":105,"geoPoint":109,"contacts":24},"Chūōku","104-0045","Japan",{"type":40,"coordinates":106},[107,108],130.67068,33.63867,{"lat":108,"lon":107},{"facility":33,"status":34,"city":111,"state":24,"zip":112,"country":104,"cosmosGeoPoint":113,"geoPoint":117,"contacts":24},"Kashiwa","227-8577",{"type":40,"coordinates":114},[115,116],139.97732,35.86224,{"lat":116,"lon":115},{"facility":33,"status":34,"city":119,"state":24,"zip":120,"country":104,"cosmosGeoPoint":121,"geoPoint":125,"contacts":24},"Kōtoku","135-8550",{"type":40,"coordinates":122},[123,124],143.14297,42.50417,{"lat":124,"lon":123},{"facility":33,"status":34,"city":127,"state":24,"zip":128,"country":129,"cosmosGeoPoint":130,"geoPoint":134,"contacts":24},"Amsterdam","1081 HV","Netherlands",{"type":40,"coordinates":131},[132,133],4.88969,52.37403,{"lat":133,"lon":132},{"facility":33,"status":34,"city":136,"state":24,"zip":137,"country":129,"cosmosGeoPoint":138,"geoPoint":142,"contacts":24},"Groningen","9713 GZ",{"type":40,"coordinates":139},[140,141],6.56667,53.21917,{"lat":141,"lon":140},{"facility":33,"status":34,"city":144,"state":24,"zip":145,"country":129,"cosmosGeoPoint":146,"geoPoint":150,"contacts":24},"Rotterdam","3015 GD",{"type":40,"coordinates":147},[148,149],4.47917,51.9225,{"lat":149,"lon":148},{"facility":33,"status":34,"city":152,"state":24,"zip":153,"country":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":24},"Seoul","03080","South Korea",{"type":40,"coordinates":156},[157,158],126.9784,37.566,{"lat":158,"lon":157},{"facility":33,"status":34,"city":152,"state":24,"zip":161,"country":154,"cosmosGeoPoint":162,"geoPoint":164,"contacts":24},"03722",{"type":40,"coordinates":163},[157,158],{"lat":158,"lon":157},{"facility":33,"status":34,"city":152,"state":24,"zip":166,"country":154,"cosmosGeoPoint":167,"geoPoint":169,"contacts":24},"05505",{"type":40,"coordinates":168},[157,158],{"lat":158,"lon":157},{"facility":33,"status":34,"city":152,"state":24,"zip":171,"country":154,"cosmosGeoPoint":172,"geoPoint":174,"contacts":24},"06351",{"type":40,"coordinates":173},[157,158],{"lat":158,"lon":157},{"facility":33,"status":34,"city":176,"state":24,"zip":177,"country":178,"cosmosGeoPoint":179,"geoPoint":183,"contacts":24},"Kaohsiung City","80756","Taiwan",{"type":40,"coordinates":180},[181,182],120.31333,22.61626,{"lat":182,"lon":181},{"facility":33,"status":34,"city":185,"state":24,"zip":186,"country":178,"cosmosGeoPoint":187,"geoPoint":191,"contacts":24},"Tainan","70403",{"type":40,"coordinates":188},[189,190],120.21333,22.99083,{"lat":190,"lon":189},{"facility":33,"status":34,"city":193,"state":24,"zip":194,"country":178,"cosmosGeoPoint":195,"geoPoint":199,"contacts":24},"Taoyuan","00333",{"type":40,"coordinates":196},[197,198],121.29696,24.99368,{"lat":198,"lon":197},{"facility":33,"status":34,"city":201,"state":24,"zip":202,"country":203,"cosmosGeoPoint":204,"geoPoint":208,"contacts":24},"Dundee","DD1 9SY","United Kingdom",{"type":40,"coordinates":205},[206,207],-2.97489,56.46913,{"lat":207,"lon":206},{"facility":33,"status":34,"city":210,"state":24,"zip":211,"country":203,"cosmosGeoPoint":212,"geoPoint":216,"contacts":24},"London","E1 1BB",{"type":40,"coordinates":213},[214,215],-0.12574,51.50853,{"lat":215,"lon":214},{"facility":33,"status":34,"city":218,"state":24,"zip":219,"country":203,"cosmosGeoPoint":220,"geoPoint":224,"contacts":24},"Metropolitan Borough of Wirral","CH63 4JY",{"type":40,"coordinates":221},[222,223],-3.10501,53.37616,{"lat":223,"lon":222},{"facility":33,"status":34,"city":226,"state":24,"zip":227,"country":203,"cosmosGeoPoint":228,"geoPoint":232,"contacts":24},"Oxford","OX3 7LE",{"type":40,"coordinates":229},[230,231],-1.25596,51.75222,{"lat":231,"lon":230},{"type":234,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100516513",false,"NCT06005493","Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","A Phase I\u002FII Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 at the time of signing the informed consent\n* Histologically confirmed diagnosis of adenocarcinoma of the stomach, gastro-esophageal junction, esophagus, or pancreas\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Must show positive CLDN18.2 expression in tumor cells as determined by central immunohistochemistry (IHC)\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening\n* Predicted life expectancy of ≥ 12 weeks\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol\n* Must have received at least one prior line of systemic therapy in the advanced\u002Fmetastatic setting\n\nKey Exclusion Criteria:\n\n* Unresolved toxicity from prior anticancer therapy of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for those defined by the protocol\n* Participant experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) \u002F macrophage activation syndrome (MAS)\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment\n* central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent\n* Infectious disease including active human immunodeficiency virus (HIV), active hepatitis B\u002FC, uncontrolled infection with EBV, uncontrolled active systemic fungal, bacterial or other infection\n* Cardiac conditions as defined by the protocol\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention\n* Participant requires chronic immunosuppressive therapy\n* Participants on anticoagulation therapy with long-acting anticoagulants or other class of anticoagulants at therapeutic doses","ALL","18 Years",{"count":244,"type":245},280,"ESTIMATED","INTERVENTIONAL",[248,249],"PHASE1","PHASE2","This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.",[252,253,254,255],"Gastric Cancer","Gastro-esophageal Junction Cancer","Pancreatic Ductal Adenocarcinoma","Esophageal Adenocarcinoma",[257,258,259,260,261,262,263,21],"CLDN18.2 \u002F Claudin 18.2","CD3","T cell-engaging bi-specific antibody","Gastric cancer","Gastro-esophageal junction cancer","Pancreatic ductal adenocarcinoma","Solid tumors","2026-02-23",{"date":266,"type":267},"2026-02-24","ACTUAL",{"date":269,"type":267},"2023-07-11",{"date":271,"type":245},"2027-07-16",{"name":5,"class":6},25]